MRG 001
Alternative Names: MRG-001Latest Information Update: 16 Oct 2024
At a glance
- Originator Miracogen
- Developer Lepu Biopharma
- Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-Hodgkin's lymphoma
Most Recent Events
- 16 Oct 2024 MRG 001 is still in phase I trials for Non-Hodgkin's lymphoma in China (Lepu Biopharma pipeline, October 2024)
- 28 Jun 2024 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma in China (IV)
- 09 Dec 2023 Efficacy and adverse event data from a Phase-I clinical trials in Non-Hodgkin's lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)